Intensity Therapeutics, Inc.
8 Wright Street
About Intensity Therapeutics, Inc.Intensity Therapeutics is a biotechnology company whose mission is to greatly extend the lives of cancer patients. Late stage solid cancer consists of well-defined visible tumors and unseen micro-metastases either in the blood or body tissue. Cancer is thus both a regional and a systemic disease. To have an effective treatment against cancer one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics was thus founded to develop a new approach to treat both the big and the small aspects of the disease - in situ vaccination. Using our DfuseRxSM platform, we create novel formulations of proven drugs. Our products have high diffusion and dispersion properties in tumors. When injected directly into a tumor or visible metastases these products are able to kill the tumors and create sites for an adaptive immune response. The observed adaptive immune response further increases the efficacy of our system to destroy or regress the tumor, eliminate secondary tumors and micrometastases as well. The Company demonstrated that complete regression (CR) of large tumors in mice is possible using the technology. Animals that had a CR became fully resistant to re-inoculation of the same cancer.
CEO: Lewis H. Bender
Chief Medical Officer: Ian B. Walters, MD
24 articles with Intensity Therapeutics, Inc.
Intensity Therapeutics' INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology
INT230-6 shows ability to regress tumors and initiate a T cell mediated systemic immune response against cancer
Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types
Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019
Intensity Therapeutics, Inc. announced positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019
Intensity Therapeutics, Inc. announced that a poster highlighting the safety profile, tumor regression activity and immune activation of the company’s lead product candidate, INT230-6, will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4, 2019 in Chicago.
Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors
Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a SalvaRx Limited portfolio company, Intensity Therapeutics, Inc. ("Intensity"). SalvaRx Limited holds an 8.5% equity interest in Intensity.
Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO Conference
The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting is taking place June 1-5 in Chicago.
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.
Study Steering Committee approves opening cohorts for dosing to deep tumors and more frequent treatment into superficial tumors
Intensity Therapeutics, Inc. Successfully Administers INT230-6 To First Patient In A Phase I/II Trial
Intensity Therapeutics, Inc. Reports That INT230-6 Induces Protective T-Cell Immunity In Preclinical Models
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6
Intensity Therapeutics, Inc. Reports That INT230-6’s Anti-Cancer Mechanism Is A Combination Of Cell Death With Immune System Activation
Intensity Therapeutics, Inc. Preclinical Results Show Anti-Cancer Synergy Of INT230-6 With Anti-PD-1 Compounds
Intensity Therapeutics, Inc. Forms Scientific Advisory Board Comprised Of World-Leading Oncologists And Scientists